SynthesisAnnals of clinical microbiology and antimicrobials2020
Klebsiella pneumoniae: an increasing threat to public health.
Synthesis in Annals of clinical microbiology and antimicrobials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 262 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
262 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Prevalence of colistin resistance in clinicalFuture microbiology · 2025Pooled it
- Antimicrobial resistance pattern of Klebsiella isolated from various clinical samples in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.The Lancet. Neurology · 2023Pooled it
- Antibiotic Resistance during COVID-19: A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- RpoE-mediated virulence attenuation elicits protective immunity in hypervirulentEmerging microbes & infections · 2026Article
- ISEmerging microbes & infections · 2026Article
- Hypervirulence-associated pseudo-compound transposons as fundamental mobile units driving cross-species virulence dissemination in Enterobacteriaceae.PLoS pathogens · 2026Article
- Bioremediation potential of lead and cadmium tolerant bacteria isolated from industrial (tannery) effluents.Journal, genetic engineering & biotechnology · 2026Article
- Whole Genome Characterization of Klebsiella Strains in European Hedgehogs and Human Nosocomial Settings Identified Shared Sequence Types, Antimicrobial Resistance Genes and Plasmids.Zoonoses and public health · 2026Article
- Draft genome sequence and resistome analysis of multidrug-resistantMicrobiology resource announcements · 2026Article
- Genomic characterization of an ESBL-producingMicrobiology spectrum · 2026Article
- Dynamics of clinicalApplied and environmental microbiology · 2026Article
- Effect of Structural Trimming on the Therapeutic Efficacy of K2 Capsule Depolymerase'sAntibiotics (Basel, Switzerland) · 2026Article
- Whole genome analysis reveals chromosomal and plasmid-mediated convergence of drug resistance in Klebsiella pneumoniae isolates.Antonie van Leeuwenhoek · 2026Article
- Genome sequences of four virulentMicrobiology resource announcements · 2026Article
- Antimicrobial resistance profiles of ESKAPE pathogens isolated in a microbiology laboratory in Somalia: a two-year retrospective study.BMC infectious diseases · 2026Article
- Pluronic F127-functionalized cerium fluoride nanocomposite: synthesis, characterization, and its enhanced antibacterial activities.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Interconnected Reservoirs: Virulence & Biofilm Traits of ESBL-Microorganisms · 2026Article
- Metagenomic Insights into Gut Microbiota Alterations FollowingInternational journal of molecular sciences · 2026Article
- Multidrug-resistant Klebsiella pneumoniae in oncology intensive care units: selected genetic markers and clinical predictors.Infection · 2026Article
202 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis review fills the paucity of information on K. pneumoniae as a nosocomial pathogen by providing pooled data on epidemiological risk factors, resistant trends and profiles and resistant and virulent genes of this organism in Asia.
methodsExhaustive search was conducted using PubMed, Web of Science, and Google scholar for most studies addressing the prevalence, risk factors, drug resistant-mediated genes and/or virulent factors of K. pneumoniae in Asia. Data extracted for meta-analysis were analyzed using comprehensive meta-analysis version 3. Trends data for the isolation rate and resistance rates were entered into Excel spread sheet and the results were presented in graphs.
resultsThe prevalence rate of drug resistance in K. pneumoniae were; amikacin (40.8%) [95% CI 31.9-50.4], aztreonam (73.3%) [95% CI 59.9-83.4], ceftazidime (75.7%) [95% CI 65.4-83.6], ciprofloxacin (59.8%) [95% CI 48.6-70.1], colistin (2.9%) [95% CI 1.8-4.4], cefotaxime (79.2%) [95% CI 68.0-87.2], cefepime (72.6) [95% CI 57.7-83.8] and imipenem (65.6%) [95% CI 30.8-89.0]. TEM (39.5%) [95% CI 15.4-70.1], SHV-11 (41.8%) [95% CI 16.2-72.6] and KPC-2 (14.6%) [95% CI 6.0-31.4] were some of the resistance mediated genes observed in this study. The most virulent factors utilized by K. pneumoniae are; hypermucoviscous phenotype and mucoviscosity-related genes, genes for biosynthesis of lipopolysaccharide, iron uptake and transport genes and finally, adhesive genes.
conclusionIt can be concluded that, antimicrobial resistant in K. pneumoniae is a clear and present danger in Asia which needs strong surveillance to curb this menace. It is very important for public healthcare departments to monitor and report changes in antimicrobial-resistant isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.